IRIS
Valenti, Mario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.140
NA - Nord America 1.635
SA - Sud America 506
EU - Europa 451
AF - Africa 66
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 4.804
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.569
SG - Singapore 1.280
CN - Cina 413
BR - Brasile 402
VN - Vietnam 231
IT - Italia 90
HK - Hong Kong 53
FR - Francia 50
IE - Irlanda 49
AR - Argentina 47
FI - Finlandia 45
IN - India 43
GB - Regno Unito 39
DE - Germania 36
CA - Canada 26
MX - Messico 25
EC - Ecuador 24
BD - Bangladesh 22
NG - Nigeria 19
NL - Olanda 19
RU - Federazione Russa 19
ZA - Sudafrica 16
BE - Belgio 14
SE - Svezia 13
ID - Indonesia 12
IQ - Iraq 12
JP - Giappone 12
PL - Polonia 12
ES - Italia 11
PK - Pakistan 11
TR - Turchia 10
UA - Ucraina 10
VE - Venezuela 8
CO - Colombia 7
GR - Grecia 7
PE - Perù 7
TN - Tunisia 7
AT - Austria 5
DZ - Algeria 5
UZ - Uzbekistan 5
AU - Australia 4
CZ - Repubblica Ceca 4
DK - Danimarca 4
JO - Giordania 4
KE - Kenya 4
MA - Marocco 4
NI - Nicaragua 4
NP - Nepal 4
RO - Romania 4
SK - Slovacchia (Repubblica Slovacca) 4
DO - Repubblica Dominicana 3
EG - Egitto 3
KZ - Kazakistan 3
LT - Lituania 3
MY - Malesia 3
PA - Panama 3
PT - Portogallo 3
SN - Senegal 3
SR - Suriname 3
AZ - Azerbaigian 2
BO - Bolivia 2
BY - Bielorussia 2
CH - Svizzera 2
CL - Cile 2
ET - Etiopia 2
JM - Giamaica 2
KW - Kuwait 2
LB - Libano 2
MT - Malta 2
OM - Oman 2
PY - Paraguay 2
QA - Qatar 2
SA - Arabia Saudita 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AO - Angola 1
BH - Bahrain 1
BN - Brunei Darussalam 1
GE - Georgia 1
GT - Guatemala 1
IL - Israele 1
IM - Isola di Man 1
KG - Kirghizistan 1
KR - Corea 1
LK - Sri Lanka 1
LV - Lettonia 1
LY - Libia 1
PH - Filippine 1
PS - Palestinian Territory 1
RS - Serbia 1
SV - El Salvador 1
TG - Togo 1
TT - Trinidad e Tobago 1
Totale 4.804
Salva come PNG Salva come JPEG
Città #
Singapore 477
Ashburn 248
San Jose 210
Shanghai 166
Chandler 150
The Dalles 144
Beijing 138
Dallas 109
Ho Chi Minh City 97
Boardman 80
Hong Kong 51
Dublin 49
New York 48
Helsinki 45
Hanoi 38
Los Angeles 38
Milan 33
São Paulo 32
Wilmington 24
San Mateo 23
Lawrence 22
Princeton 22
Santa Clara 20
Benin City 19
Paris 18
Orem 15
Brussels 13
Phoenix 13
Amsterdam 12
Brooklyn 12
Rio de Janeiro 12
Seattle 12
Tokyo 11
Ann Arbor 9
Chennai 9
Da Nang 9
Guayaquil 9
Johannesburg 9
London 9
Assago 8
Montreal 8
Belo Horizonte 7
Duncan 7
Haiphong 7
Mexico City 7
Mogi das Cruzes 7
Munich 7
Poplar 7
Salvador 7
Baghdad 6
Buenos Aires 6
Can Tho 6
Curitiba 6
Frankfurt am Main 6
Moscow 6
Quito 6
Boston 5
Charlotte 5
Chicago 5
Falkenstein 5
Hải Dương 5
Lima 5
New Delhi 5
Rome 5
Uberlândia 5
Warsaw 5
Amman 4
Atlanta 4
Bergamo 4
Biên Hòa 4
Bratislava 4
Brno 4
Caracas 4
Caraguatatuba 4
Council Bluffs 4
Dhaka 4
Esbjerg 4
Feira de Santana 4
Goiânia 4
Kyiv 4
Managua 4
Manchester 4
Nairobi 4
Porto Alegre 4
Quảng Ngãi 4
San Francisco 4
São Bernardo do Campo 4
Tashkent 4
Thái Bình 4
Tunis 4
Uberaba 4
Wroclaw 4
Aguascalientes 3
Anápolis 3
Arapiraca 3
Brasília 3
Cabo Frio 3
Calgary 3
Catania 3
Dakar 3
Totale 2.747
Salva come PNG Salva come JPEG
Nome #
Melanoma in Adolescents and Young Adults (AYAs): An Italian Multi-Centric Retrospective Experience 201
Rosacea-like Acute Reaction After Hyaluronic Acid Dermal Filler 110
Chronic Hand Eczema (CHE): A Narrative Review 109
Brodalumab: a new way to inhibit IL-17 in psoriasis 108
A fatal case of COVID-19 infection presenting with an erythema multiforme-like eruption and fever 94
Specific Infiltrate of Hodgkin Lymphoma at Site of Cellulitis Mimicking Secondary Cutaneous Involvement 90
Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 86
Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: A single-center retrospective comparative study 84
Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single- center real-life population 79
Apremilast for the treatment of palmo-plantar non-pustular psoriasis: A real-life single-center retrospective study 79
Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study 76
Complicated coronavirus disease 2019 (COVID-19) in a psoriatic patient treated with ixekizumab 71
Reorganization of a Northern Italy dermatology department during the COVID-19 pandemic: is it temporary or the beginning of a new era in dermatology? 70
A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeks 66
Generalized pustular psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA COVID-19 vaccine, successfully treated with risankizumab 64
Impact of delay in follow-up due to COVID-19 pandemic on skin cancer progression: a real-life experience from an Italian hub hospital 63
Palmar nodules in a young woman with ulcerative colitis and enteropathic arthritis 63
Non-complicated evolution of COVID-19 infection in a patient with psoriasis and psoriatic arthritis during treatment with adalimumab 63
Effects of TNF-α inhibition on pre-clinical enthesitis: observational study on 49 psoriatic patients 63
A 3-Year Multicentric Study on Switching from Ustekinumab to Guselkumab in Partial Responders with Psoriasis—IL PSO (Italian Landscape Psoriasis) 61
Concomitant Pyoderma Gangrenosum-like and Amicrobial Pustulosis of the Folds: a Case Report 61
A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS) 60
Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study 58
Noninvasive Assessment and Management of Folliculitis Decalvans by Trichoscopy and Reflectance Confocal Microscopy 54
Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis) 53
Urticarial rash in autoinflammatory syndromes 52
Real-Life Effectiveness and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Single-Center 16-Week Study 51
Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050 51
Early predictors of psoriatic arthritis: a delphi based consensus from Italian dermatology centers 51
Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis) 50
Real-life efficacy of guselkumab in patients with early psoriatic arthritis 50
Risk of peripheral neuropathy in patients with psoriasis and psoriatic arthritis. A prospective cohort study 49
Multiple facial angiofibromas: A manifestation of Frank-ter Haar syndrome? 49
Bullous vasculitis associated with Streptococcus pyogenes sepsis 49
Bone marrow metastases: a systematic review of a neglected involvement in malignant melanoma 48
Cutaneous toxicity of CAR T-cell therapy: Case report of a bullous life-threatening reaction 48
Paradoxical Psoriasis: An Updated Review of Clinical Features, Pathogenesis, and Treatment Options 48
Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study 48
Pregnancy outcome of a patient treated with upadacitinib for severe atopic dermatitis 47
Practical Use of Upadacitinib in Patients with Severe Atopic Dermatitis in a Real-World Setting: A Systematic Review 47
Biologics for the Treatment of Severe Acrodermatitis Continua of Hallopeau: Report of Two Cases Successfully Treated with Ixekizumab and Ustekinumab 47
Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study 47
Global, regional, and national stillbirths at 20 weeks' gestation or longer in 204 countries and territories, 1990–2021: findings from the Global Burden of Disease Study 2021 46
Combination intravenous immunoglobulin, oral prednisone, and methotrexate for managing scleromyxedema: case report and literature discussion 46
What Can IBD Specialists Learn from IL-23 Trials in Dermatology? 46
Disease Severity Is Associated with Alexithymia in Patients with Atopic Dermatitis 45
Efficacy and tolerability of tirbanibulin 1% ointment in the treatment of cancerization field: a real‐life Italian multicenter observational study of 250 patients 44
Safety of anti-IL-23 drugs in patients with moderate-to-severe plaque psoriasis and previous tuberculosis infection: a monocentric retrospective study 44
Arrhythmias and other cardiovascular diseases in young patients (<40 years) with moderate/severe atopic dermatitis: A multicentric study in northern Italy 44
Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study 42
Skin cancers: how to balance the risks and benefits of surgery during COVID-19 pandemic (a Northern Italy single-center experience) 42
Spesolimab in patients with flare of generalized pustular psoriasis: A multicentre case‐series 41
Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience 41
Effectiveness and safety of upadacitinib for moderate‐to‐severe atopic dermatitis in a real‐world setting: A 52‐week retrospective study 41
Guidelines How to Integrate Surgery and Targeted Therapy with Biologics for the Treatment of Hidradenitis Suppurativa: Delphi Consensus Statements from an Italian Expert Panel 41
Safety of Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Viral Hepatitis: A Monocentric Retrospective Study 41
Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers 41
Real-life Effectiveness and Safety of Guselkumab in Moderate-to-Severe Plaque Psoriasis: A 104-Week Retrospective Single-Center Study 41
Pembrolizumab-induced plaque psoriasis successfully treated with risankizumab in a patient with stage IV cutaneous melanoma 40
Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study – IL PSO (Italian landscape psoriasis) 39
Dupilumab for the treatment of atopic dermatitis of the elderly: a real-life 52-week experience 39
Intra-Class Switch Among IL-23 Inhibitors for Plaque Psoriasis: Is It Worth It? 39
Anti-IL-17/23 Drugs for the Treatment of Moderate-to-Severe Hidradenitis Suppurativa in Patients With Concomitant Psoriasis: A Multicenter Retrospective Study 39
Efficacy and safety of switching psoriatic patients to bimekizumab: new evidence from clinical trials 39
Risankizumab for the treatment of genital psoriasis: A 1-year, real-world experience 38
Topical Pharmacological Treatment of Actinic Keratoses: Focus on Tirbanibulin 1% Ointment 38
Geometric contour variation in clinical target volume of axillary lymph nodes in breast cancer radiotherapy: an AIRO multi-institutional study 37
An updated safety review of Hidradenitis Suppurativa treatment options 37
A severe case of IgA bullous pemphigoid successfully treated with dupilumab 37
Real-life effectiveness and safety of dupilumab in adolescents with atopic dermatitis: a 52-week single-center retrospective study 37
Atypical facial pustular folliculitis by Klebsiella pneumoniae: a case report 37
Apremilast for the treatment of pustular psoriasis induced by neoadjuvant ifosfamide + etoposide chemotherapy for Ewing Sarcoma: a case report 37
Successful use of tralokinumab for the treatment of atopic dermatitis on the genitals 36
Upadacitinib for the treatment of atopic dermatitis in the elderly: an Italian case series of seven patients 36
Sub-erythrodermic psoriasis successfully treated with bimekizumab: A case report 36
Optimizing Tildrakizumab Dosing in Psoriasis: A 52-Week Multicenter Retrospective Study Comparing 100 mg and 200 mg-IL PSO (Italian Landscape Psoriasis) 36
The impact of biologic therapy for moderate-to-severe psoriasis on the immune responses to SARS-CoV-2 infection and vaccination 35
Real-World Effectiveness and Safety of Upadacitinib and Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Study 35
Effectiveness of ixekizumab for the treatment of moderate‐to‐severe plaque psoriasis with involvement of difficult‐to‐treat areas: A 52‐week multicenter retrospective study 35
Long-Term Sequential Digital Dermoscopy of Low-Risk Patients May Not Improve Early Diagnosis of Melanoma Compared to Periodical Handheld Dermoscopy 35
Anorectal melanoma: systematic review of the current literature of an aggressive type of melanoma 35
Long-term management of pediatric psoriasis with ixekizumab: a case report 35
Effectiveness and Safety of Biological Therapies in Very Severe Plaque Psoriasis: A Real-Life Retrospective Study 34
Intra-class switch among interleukin-17 inhibitors for the treatment of plaque psoriasis: a single-center experience 34
Methotrexate-Induced Mucositis in a Patient With Angioimmunoblastic T-cell Lymphoma 34
Connective tissue panniculitis and vitiligo in a patient with stage IV melanoma achieving complete response to dabrafenib and trametinib combination therapy 33
Potential Role of Leptin in JAK2 Inhibitor-Associated Weight Gain: A Monocentric Retrospective Study 32
Nonadherence to immune-modifying therapies during the COVID-19 pandemic: the crucial role of doctor-patient communication in avoiding drug discontinuation 32
Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience 31
Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study - IL PSO (Italian landscape psoriasis) 30
Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study 30
Thin Amelanotic and Hypomelanotic Melanoma: Clinicopathological and Dermoscopic Features 30
New and Emerging Biologics and Jak Inhibitors for the Treatment of Prurigo Nodularis: A Narrative Review 28
Effectiveness and safety of anti-IL-23 and anti-IL-17 biological therapies for psoriasis in elderly patients: Real-world experience from two Italian hospitals 28
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study-IL PSO (ITALIAN LANDSCAPE PSORIASIS) 27
Safety of Interleukin Inhibitors in Patients with Plaque Psoriasis and Neoplasm: A Retrospective Study from Two Referral Centers 27
Serum Lipids Alterations in Patients Under Systemic JAK Inhibitors Treatments in Dermatology: Clinical Aspects and Management 26
New-onset and flares of psoriasis after COVID-19 infection or vaccination successfully treated with biologics: a case series 22
State of health and inequalities among Italian regions from 2000 to 2021: a systematic analysis based on the Global Burden of Disease Study 2021 20
Age-Related Variations in Clinical, Histological, and Genetic Characteristics in Multiple and Familial Melanomas: A Study of 333 Patients 15
Totale 4.904
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.352
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.352
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202119 0 0 0 0 0 0 0 0 0 7 1 11
2021/2022110 1 0 3 13 2 3 5 10 26 8 32 7
2022/2023359 55 28 25 58 33 27 0 29 55 29 20 0
2023/2024528 16 37 98 28 11 49 59 45 12 22 52 99
2024/20251.163 13 35 14 19 5 105 87 61 161 222 216 225
2025/20262.688 440 242 217 285 183 142 748 168 140 123 0 0
Totale 4.904